Store Locator
Back
Oxidative stress and mitochondrial damage have been implicated in age-related cognitive decline and many chronic diseases. Cogni-Q® contains a high dose of the well-known antioxidant Coenzyme Q10 along with Pyrroloquinoline Quinone (PQQ), a recently discovered B-vitamin-like nutrient. PQQ and CoQ10 have been studied in combination and were shown to improve memory and cognition in elderly subjects after just 3 months. They have also been shown to reduce neurodegeneration thanks to their antioxidant functions, their ability to reduce mitochondrial damage, and their involvement in cellular energy production. PQQ has shown the unique ability to signal and activate the generation of new mitochondria, an action that no other nutrient can do.
AOR Advantage
AOR’s Cogni-Q® is a powerful formula for those who are concerned with supporting a healthy aging brain, protecting their cognitive health, healing the brain after injury and providing the body and brain with antioxidant protection in just one capsule a day. PQQ is an essential nutrient, meaning that your body cannot produce it on its own and it must therefore be obtained from diet or supplements. More recent research indicates that PQQ’s unique nutritional profile provides antioxidant protection alone and even more so in combination with CoQ10. AOR’s formula combines both of these outstanding antioxidants in clinically studied combined doses in order to offer excellent antioxidant activity.
80030871
Cogni-Q® provides pyrroloquinoline quinone (PQQ), a B vitamin like nutrient, and coenzyme Q10 (CoQ10) as antioxidants for protection against oxidative stress and for the maintenance of good health.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Take one capsule daily with food, or as directed by a qualified health care practitioner.
Do not use if pregnant or breastfeeding. Consult a health care practitioner prior to use if you are taking blood thinners or blood pressure medication, or for use beyond 12 weeks. May cause cold, abdominal symptoms, headache, fatigue and diarrhea.
- Mitochondrial function
- Cognitive support
- Antioxidant
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Non-medicinal Ingredients: dibasic calcium phosphate, silicon dioxide and sodium stearyl fumarate.
Capsule: hypromellose, glycerin and purified water.
Cardiovascular Effects
Study #1: Treatment of essential hypertension with coenzyme Q10
In a clinical trial of 109 patients with essential hypertension, patients were individually given CoQ10. Doses varied until blood levels reached >2mcg/mL. The functional status of hypertensive patients improved with the need to gradually decrease any antihypertensive pharmaceutical treatment the patient was previously taking within one to six months of CoQ10 supplementation. 51% of patients were completely taken off their antihypertensive drugs by about 4 months of CoQ10 use. Patients also showed significantly improved blood pressure measurements (both systolic and diastolic) and New York Heart Association (NYHA) functional class status (p<0.001). Echocardiograms before and during treatment showed significant improvements in left ventricular wall thickness and diastolic function after CoQ10 supplementation.
Study #2: Coenzyme Q10 in essential hypertension
In this study, 26 patients with essential arterial hypertension were treated with 100mg CoQ10 for 10 weeks. At the end of the treatment period, systolic and diastolic blood pressures significantly decreased by 17mmHg and 12mmHg, respectively (P<0.0001). Serum total cholesterol significantly decreased and serum HDL cholesterol was significantly increased after treatment as well.
Study #3: Effects of pyrroloquinoline quinone disodium salt intake on the serum cholesterol levels
In a double-blind, placebo-controlled trial, 29 healthy Japanese adults with normal to moderately high triglyceride levels (110-300mg/dL) were randomized to receive 20mg of pyrroloquinoline quinone (PQQ) daily. After 12 weeks of treatment there was a significant decrease in mean LDL cholesterol levels in the PQQ group. In the subgroup of subjects who had high LDL levels at baseline, PQQ led to significant decreases from baseline, in LDL compared to placebo.
Effects on Fertility
Study #1: Mitochondrial function of oocytes and sperm
As women age there is a corresponding decrease in the function of oocyte mitochondria. In an animal model of reproductive aging, aged mice were treated with CoQ10 for 15 weeks. Treated mice had increased numbers of primordial, preantral and antral follicles, compared to aged-matched controls. The magnitude of ovarian reserve was statistically significant in these CoQ10-treated mice. Researchers then conducted a breeding trial and found that the reduced litter size in control animals was normalized with CoQ10 treatment. Overall, CoQ10 supplementation resulted in improved mitochondrial activity in oocytes, an increase in oocytes ovulated in aged mice and more pups born.
Study #2: Improved ovarian response and embryo quality
In a prospective, randomized controlled study, 169 patients younger than 35 years with poor ovarian response (low AMH levels, low antral follicle counts) were randomized to 600mg daily of CoQ10, for 60 days, before entering an in-vitro fertilization (IVF) cycle. Women pretreated with CoQ10 had significantly lower requirements for gonadotrophin and had higher peak levels of estradiol. The results during the IVF cycle were that treated women had an increased number of oocytes retrieved, higher fertilization rates (67%) and higher quality embryos (p<0.05). There were significantly fewer embryo transfers that had to be canceled in women treated with CoQ10 (due to poor embryo development), compared to controls.
Study #3: Effects of the reduced form of coenzyme Q10 (ubiquinol) on semen
In a double-blind, randomized placebo-controlled study, 228 men with idiopathic oligoasthenoteratozoospermia (low sperm count, poor motility and abnormal morphology) were randomized to receive 200mg of CoQ10 daily for 26 weeks. Treatment with CoQ10 led to significant improvements in mean sperm density [28.7× 10(6)/ml in the CoQ10 group and 16.8 × 10(6)/ml in the placebo group (p = 0.005)], sperm motility [35.8% in CoQ10 group and 25.4% in placebo group (p = 0.008)] and morphology [17.6% in CoQ10 group and 14.8% in placebo group (p=0.01)]
Neurological Effects
Study #1: The effect of Pyrroloquinoline quinone (PQQ) on cognition
The effect of Pyrroloquinoline quinone (PQQ) on cognition was tested in 41 healthy elderly subjects. Subjects were given 20mg of PQQ or placebo for 12 weeks. In the group with the lowest initial score on visual-spatial cognitive function (via laptop tablet Touch M), scores were significantly increased after PQQ supplementation. Researchers also noted that PQQ administration led to increased cerebral blood flow in the prefrontal cortex, as measured by near-infrared spectrometry.
Study #2: Effects of antioxidant supplements (BioPQQ) on the cerebral blood flow and oxygen metabolism
In another study of healthy adults aged 50-70 years, researchers measured regional cerebral blood flow (rCBF) and oxygen metabolism in the prefrontal cortex (PFC) before and after 12 weeks of supplementation with PQQ. 20 subjects were given 20mg PQQ or placebo daily. The result of PQQ supplementation was a significant increase in hemoglobin levels in the right PFC (p<0.05). Researchers also noted decreases in oxygen saturation in this same area after PQQ, likely from increased oxygen metabolism, which researchers concluded may result in enhanced cognitive function.
Study #3: Mitochondrial regulation by pyrroloquinoline quinone
In an animal model of Parkinson’s disease, rats were given either PQQ or the medication Edaravone intraperitoneally daily for 8 weeks. In the initial in vitro study involving cultured human neuroblastoma cells, the presence of PQQ protected mitochondria from morphology damage. In the in vivo animal study, PQQ was found to upregulate genes related to mitochondrial biogenesis, thereby preventing mitochondrial dysfunction and promoting mitochondrial biogenesis. Researchers concluded that these may account for PQQ’s neuroprotective effect in models of Parkinson’s disease.
